Detalles de la búsqueda
1.
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study.
Oncologist
; 29(3): e372-e381, 2024 Mar 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37796838
2.
Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study.
Acta Oncol
; 63: 213-219, 2024 Apr 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-38647024
3.
Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy.
Future Oncol
; 18(23): 2593-2604, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35722877
4.
Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy.
Future Oncol
; 15(23): 2743-2757, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31339060
5.
Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.
Handb Exp Pharmacol
; 249: 63-89, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-28332047
6.
Treatment of lung large cell neuroendocrine carcinoma.
Tumour Biol
; 37(6): 7047-57, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-26943800
7.
Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.
Tumour Biol
; 37(10): 12991-13003, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27460087
8.
Uncommon breast metastatic site and eribulin responsiveness in a heavily pretreated patient.
Future Oncol
; 10(15): 2417-22, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25525850
9.
Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs.
Tumori
; : 3008916241246659, 2024 Apr 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38623748
10.
Management of patients with extensive small-cell lung cancer in the immunotherapy era: an Italian consensus through a Delphi approach.
Crit Rev Oncol Hematol
; : 104247, 2024 Jan 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-38307393
11.
Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund.
Tumori
; : 3008916241229287, 2024 Feb 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38372045
12.
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research.
Clin Lung Cancer
; 25(2): 190-195, 2024 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38262770
13.
New options and open issues in the management of unresectable stage III and in early-stage NSCLC: A report from an expert panel of Italian medical and radiation oncologists - INTERACTION group.
Crit Rev Oncol Hematol
; 190: 104108, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37633350
14.
Amivantamab Compared with Real-World Physician's Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating EGFR Exon 20 Insertion Mutations.
Cancers (Basel)
; 15(22)2023 Nov 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38001589
15.
Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative Results.
Clin Lung Cancer
; 24(5): 467-473, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37061413
16.
Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations.
Clin Lung Cancer
; 24(7): 631-640.e2, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37775370
17.
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors.
Lung Cancer
; 186: 107417, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37918061
18.
STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines.
J Thorac Oncol
; 18(8): 1070-1081, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37094664
19.
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis.
J Immunother Cancer
; 11(6)2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37286305
20.
Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care.
JCO Precis Oncol
; 7: e2300067, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37487147